Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Kornegay JN, Spurney CF, Nghiem PP, Brinkmeyer-Langford CL, Hoffman EP, Nagaraju K.

ILAR J. 2014;55(1):119-49. doi: 10.1093/ilar/ilu011. Review.

2.

The golden retriever model of Duchenne muscular dystrophy.

Kornegay JN.

Skelet Muscle. 2017 May 19;7(1):9. doi: 10.1186/s13395-017-0124-z. Review.

3.

Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.

Kornegay JN, Bogan JR, Bogan DJ, Childers MK, Li J, Nghiem P, Detwiler DA, Larsen CA, Grange RW, Bhavaraju-Sanka RK, Tou S, Keene BP, Howard JF Jr, Wang J, Fan Z, Schatzberg SJ, Styner MA, Flanigan KM, Xiao X, Hoffman EP.

Mamm Genome. 2012 Feb;23(1-2):85-108. doi: 10.1007/s00335-011-9382-y. Epub 2012 Jan 5. Review.

4.

Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy.

Wuebbles RD, Sarathy A, Kornegay JN, Burkin DJ.

Dis Model Mech. 2013 Sep;6(5):1175-84. doi: 10.1242/dmm.012211. Epub 2013 Jul 11.

5.

The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies.

Banks GB, Chamberlain JS.

Curr Top Dev Biol. 2008;84:431-53. doi: 10.1016/S0070-2153(08)00609-1. Review.

PMID:
19186250
6.

Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.

Vieira NM, Spinazzola JM, Alexander MS, Moreira YB, Kawahara G, Gibbs DE, Mead LC, Verjovski-Almeida S, Zatz M, Kunkel LM.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6080-6085. doi: 10.1073/pnas.1703556114. Epub 2017 May 22.

7.

Levels of inflammation and oxidative stress, and a role for taurine in dystropathology of the Golden Retriever Muscular Dystrophy dog model for Duchenne Muscular Dystrophy.

Terrill JR, Duong MN, Turner R, Le Guiner C, Boyatzis A, Kettle AJ, Grounds MD, Arthur PG.

Redox Biol. 2016 Oct;9:276-286. doi: 10.1016/j.redox.2016.08.016. Epub 2016 Aug 30.

8.

Identification in GRMD dog muscle of critical miRNAs involved in pathophysiology and effects associated with MuStem cell transplantation.

Robriquet F, Babarit C, Larcher T, Dubreil L, Ledevin M, Goubin H, Rouger K, Guével L.

BMC Musculoskelet Disord. 2016 May 11;17:209. doi: 10.1186/s12891-016-1060-5.

9.

Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy.

Moulton HM, Moulton JD.

Biochim Biophys Acta. 2010 Dec;1798(12):2296-303. doi: 10.1016/j.bbamem.2010.02.012. Epub 2010 Feb 17.

10.

Predictive markers of clinical outcome in the GRMD dog model of Duchenne muscular dystrophy.

Barthélémy I, Pinto-Mariz F, Yada E, Desquilbet L, Savino W, Silva-Barbosa SD, Faussat AM, Mouly V, Voit T, Blot S, Butler-Browne G.

Dis Model Mech. 2014 Nov;7(11):1253-61. doi: 10.1242/dmm.016014. Epub 2014 Sep 26.

11.

Genome-wide association study to identify potential genetic modifiers in a canine model for Duchenne muscular dystrophy.

Brinkmeyer-Langford C, Balog-Alvarez C, Cai JJ, Davis BW, Kornegay JN.

BMC Genomics. 2016 Aug 22;17:665. doi: 10.1186/s12864-016-2948-z.

12.

Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.

Church JE, Trieu J, Chee A, Naim T, Gehrig SM, Lamon S, Angelini C, Russell AP, Lynch GS.

Exp Physiol. 2014 Apr;99(4):675-87. doi: 10.1113/expphysiol.2013.077255. Epub 2014 Jan 17.

13.

Why short stature is beneficial in Duchenne muscular dystrophy.

Bodor M, McDonald CM.

Muscle Nerve. 2013 Sep;48(3):336-42. doi: 10.1002/mus.23793. Epub 2013 Jul 27.

PMID:
23893308
14.

Use of the six-minute walk test to characterize golden retriever muscular dystrophy.

Acosta AR, Van Wie E, Stoughton WB, Bettis AK, Barnett HH, LaBrie NR, Balog-Alvarez CJ, Nghiem PP, Cummings KJ, Kornegay JN.

Neuromuscul Disord. 2016 Dec;26(12):865-872. doi: 10.1016/j.nmd.2016.09.024. Epub 2016 Oct 3.

PMID:
27818009
15.

What do animal models have to tell us regarding Duchenne muscular dystrophy?

Wells DJ, Wells KE.

Acta Myol. 2005 Dec;24(3):172-80. Review.

PMID:
16629050
16.

Whole genome sequencing reveals a 7 base-pair deletion in DMD exon 42 in a dog with muscular dystrophy.

Nghiem PP, Bello L, Balog-Alvarez C, López SM, Bettis A, Barnett H, Hernandez B, Schatzberg SJ, Piercy RJ, Kornegay JN.

Mamm Genome. 2017 Apr;28(3-4):106-113. doi: 10.1007/s00335-016-9675-2. Epub 2016 Dec 27.

17.

Translating golden retriever muscular dystrophy microarray findings to novel biomarkers for cardiac/skeletal muscle function in Duchenne muscular dystrophy.

Galindo CL, Soslow JH, Brinkmeyer-Langford CL, Gupte M, Smith HM, Sengsayadeth S, Sawyer DB, Benson DW, Kornegay JN, Markham LW.

Pediatr Res. 2016 Apr;79(4):629-36. doi: 10.1038/pr.2015.257. Epub 2015 Dec 16.

18.

Drug Discovery of Therapies for Duchenne Muscular Dystrophy.

Blat Y, Blat S.

J Biomol Screen. 2015 Dec;20(10):1189-203. doi: 10.1177/1087057115586535. Epub 2015 May 14. Review.

PMID:
25975656
19.

Current Translational Research and Murine Models For Duchenne Muscular Dystrophy.

Rodrigues M, Echigoya Y, Fukada SI, Yokota T.

J Neuromuscul Dis. 2016 Mar 3;3(1):29-48. Review.

20.

Brain function in Duchenne muscular dystrophy.

Anderson JL, Head SI, Rae C, Morley JW.

Brain. 2002 Jan;125(Pt 1):4-13. Review.

PMID:
11834588

Supplemental Content

Support Center